

### AGENDA

AGENDA Thursday N	lovember 11, 2022				
TIME	PRESENTATION	SPEAKER(S)			
7:00 AM	Registration				
8:00 AM	Welcome	R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)			
8:10 AM	Symposium Introduction	Ashrith Guha, MD, MPH FACC			
	Plenary Session I				
	Moderators: Kelly H. Schlendorf, MD, Ju Kim, MD, She	elley Hall, MD, Annette Jackson, MD			
8:17 AM	State-of-Art-Lecture I Rejection of the Heart: Past, Present and Future	Mario Deng, MD, FACC, FESC			
8:57 AM	Molecular Mechanisms acute rejection: Novel Insights	Xian Chang Li, MD, PhD			
9:17 AM	Cell Free DNA - What does it add to diagnosing rejection	Shelley Hall, MD, FACC, FHFSA, FAST			
9:37 AM	Question and Answer Discussion	Kelly H. Schlendorf, MD, Ju Kim, MD, Shelley Hall, MD, Annette Jackson, MD			
9:52 AM	Break and Exhibits				
	Plenary Session II Moderators: Mary Jane Farr, MD, Shelley Hall, MD, Irr	ad Hussain, MD and Mario Deng, MD			
10:07 AM	DSAs - Which are Important and What to do About Them?	Todd N. Eagar, PhD			
10:27 AM	CMR/PET Imaging in Management of Rejection?	Dipan J. Shah, MD, FACC			
10:47 AM	Non-HLA Antibodies? When do you Test and what to do About Them?	Annette Jackson, MD			
11:07 AM	Managing Sensitized Patient Prior to Transplantation	Marlena Habal, MD, FRCPC			
11:27 AM	Question and Answer Discussion	Mary Jane Farr, MD, Shelley Hall, MD, Imad Hussain, MD and Mario Deng, MD			
11:42 AM	Lunch and Exhibits				
	Plenary Session III	,			
	Moderators: Sepna Legha, MD, Mary Jane Farr, MD, H				
12:27 PM	Case Discussions	Case#1: <u>Lauren Truby, MD</u> Case#2: <u>Salil Kumar, MD</u> Case#3: <u>Kelsey Patel, MD</u> Case#4: <u>Matthew Riesbeck, MD</u>			
1:47 PM	Novel Immunosuppressive agents: Role in the Era of Generics	Alex Rogers, PharmD, BCPS			
2:07 PM	Positive Crossmatch: Back to Cytotoxic crossmatch? Relevance and Management	Annette M Jackson, PhD, F(ACHI)			
2:27 PM	Question and Answer / Case Discussions – Putting it into Practice	Sepna Legha, MD, Mary Jane Farr, MD, Kelly Schlendorf, MD and Mahwash Kassi, MD			
2:42 PM	Break and Exhibits	-			
	Plenary Session IV Moderators: Rayan Yousefzai, MD, Mario Deng, MD, Annette Jackson, MD and Nadia Fida, MD				
2:57 PM	DEBATE Immunosuppression: Tailoring Care or Standardizing Protocols for Better Outcomes Kelly Schlendorf, MD: <u>Standardizing Protocols</u>	Kelly Schlendorf, MD Mary Jane Farr, MD,			
	Mary Jane Farr, MD: <u>Tailoring Protocols</u>				
3:37 PM	Rebuttal				



3:47 PM	Role of Photopheresis in Rejection	Ashrith Guha, MD, MPH FACC
3:59 PM	Is There Chronic AMR in the Heart?	Arvind Bhimaraj, MD
4:11 PM	Rejection in Multi-Organ Transplantation	Cindy Martin, MD
4:23 PM	Biopsy Negative Rejection in the Current Era	Janardhana Rao Gorthi, MD
4:35 PM	Question and Answer Discussion	Rayan Yousefzai, MD, Mario Deng, MD, Annette Jackson, MD and Nadia Fida, MD
4:50 PM	Conclusion	Cindy Martin, MD
5:00 PM	Adjournment	

#### FACULTY

#### COURSE DIRECTOR

#### R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)

J.C. Walter Jr. Presidential Distinguished Chair Director, J.C. Walter Jr. Transplant Center Director, Transplantation Research Chief, Division of Transplantation, Department of Surgery Professor of Surgery Weill Cornell Medical College Houston Methodist

#### HOUSTON METHODIST FACULTY

#### Todd N. Eagar, PhD

Assistant Professor of Pathology and Genomic Medicine, Academic Institute Assistant Member, Research Institute Houston Methodist Weill Cornell Medical College

#### Ashrith Guha, MD, MPH FACC

Medical Director, Heart Transplant and MCS Program(JCWTC) Director, Pulmonary Hypertension and Right Heart Failure Program(MDHAVC) Assistant Professor of Cardiology, Houston Methodist Institute for Academic Medicine Assistant Professor of Medicine, Weill Cornell Medical College Houston Methodist Hospital

#### Xian Chang Li, MD, PhD

Max and Lillie Frosch Centennial Chair in Transplant Research, Immunobiology & Transplant Science Center Professor of Transplant Immunology in Surgery, Academic Institute Full Member, Research Institute Director, Immunobiology & Transplant Science Center Houston Methodist Weill Cornell Medical College



#### Alex Rogers, PharmD, BCPS

Senior Pharmacy Clinical Specialist, Solid Organ Transplant Houston Methodist

#### Dipan J. Shah, MD, FACC

Beverly B. and Daniel C. Arnold Distinguished Centennial Chair, Department of Cardiology Professor of Cardiology, Academic Institute Full Member, Research Institute Houston Methodist Weill Cornell Medical College

#### Rayan Yousefzai, MD

Assistant Professor of Cardiology, Academic Institute Assistant Clinical Member, Research Institute Houston Methodist Weill Cornell Medical College

#### **GUEST FACULTY**

#### Mario Deng, MD, FACC, FESC

Professor of Medicine Advanced Heart Failure/Mechanical Support/Heart Transplant David Geffen School of Medicine at UCLA Ronald Reagan UCLA Medical Center Santa Monica, California

#### Maryjane Farr, MD, MSc, FACC, FAST

Section Chief of Heart Failure, Mechanical Circulatory Support and Transplant Jackie and Charles Solomon Distinguished Chair in Clinical Excellence UT Southwestern Medical Center Dallas, TX

#### Marlena Habal, MD, FRCPC

Assistant Professor of Medicine NYU Grossman School of Medicine NYU Langone New York, NY



#### Shelley Hall, MD, FACC, FHFSA, FAST

Chief, Department of Advanced Heart Failure, Mechanical Circulatory Support and Transplant Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute Baylor University Medical Center Dallas, TX

#### Annette M Jackson, PhD, F(ACHI)

Associate Professor in Surgery Associate Professor in Immunology Duke Surgery Duke University School of Medicine

#### Kelly H. Schlendorf, MD, MHS

Director, Heart Failure and Transplant Medical Director, Adult Heart Transplant Program Assistant Professor of Medicine Vanderbilt Health Nashville, TN

#### MODERATORS

#### Imad Hussain, MD

Assistant Professor of Cardiology, Academic Institute Assistant Clinical Member, Research Institute Program Director, Advanced Heart Failure and Transplant Cardiology Fellowship, Department of Cardiology Houston Methodist Weill Cornell Medical College

#### Ju Kim, MD, FACC

Interim Medical Director, Cardiac Intensive Care Unit Houston Methodist DeBakey Cardiology Associates Assistant Professor of Cardiology, Academic Institute Assistant Clinical Member, Research Institute Houston Methodist Weill Cornell Medical College

#### Kelly H. Schlendorf, MD, MHS

Director, Heart Failure and Transplant Medical Director, Adult Heart Transplant Program Assistant Professor of Medicine



#### MODERATORS

Salil Kumar, MD Medical Resident Houston Methodist

#### Kelsey Patel, MD

Medical Resident Houston Methodist

#### Matthew Riesbeck, MD

Medical Resident Baylor College of Medicine

#### Lauren Truby, MD

Medical Resident UT Southwestern

#### **PROGRAM OVERVIEW**

The Houston Methodist J.C. Walter Jr. Transplant Center is proud to introduce its leading educational event of the year. This program is designed to provide an innovative view on strategies for the widespread issues of organ failure management. Renowned national and international speakers will share their state-of-the-art techniques and advanced research to educate attendees on the advancements of organ failure management.

#### TARGET AUDIENCE

The George P. Noon Conference Series is designed for nephrologists, cardiologists, gastroenterologists, hepatologists, pulmonologists, pathologists, internists, oncologists, physicians treating patients with organ failure, nurses, family practitioners, social workers and allied health professionals with an interest in organ failure transplant management.

#### EDUCATIONAL OBJECTIVES

Upon completion of this course, the participant should be able to:

- Analyze the past, present and future of heart rejection
- Distinguish the difference of tailoring care or standardizing Immunosuppression protocols for better outcomes
- Explain the relevance and management of positive Cross-match
- Indicate when to test for Non-HLA antibodies and what to do about them
- Assess the latest treatment options for heart failure management
- Deliberate the pros and cons of surgical and nonsurgical management of heart failure

#### NURSING OUTCOMES STATEMENT

Nurses attending this activity will be able to provide high quality care based on an enriched understanding of current research, emerging treatments and procedures related to mechanisms of heart transplant rejection, novel approaches to immunosuppression, and cases for tailoring vs customization of treatment. They will be able to identify at least one new learning related to innovations in the management of heart failure with mechanical support devices.

#### EDUCATION METHODS

Didactic lectures, panel discussion



#### **EVALUATION METHOD**

Evaluation by questionnaire will address program content, presentation, and possible bias.

#### ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

#### Physicians

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Nurses

Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will provide up to 7.5 contact hours for this activity. Participants must attend each session in its entirety and complete the corresponding items on the evaluation tool.

#### Transplant Coordinators

This course has been approved by the American Board for Transplant Certification for 7.75 Category I CEPTCs.

#### Social Workers

Houston Methodist and J.C. Walter Jr. Transplant Center designate this activity for 7.0 CEU for social work. This offering complies with section 781.509 of the rules of the Texas State Board of Social Work Examiners.

#### HOW TO RECEIVE YOUR CERTIFICATE

Physicians

An email will be sent from <u>learn@houstonmethodist.org</u> with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

#### Nurses

To be awarded up to 7.5 contact hours for this continuing education activity, the participant must:

- Be sure to check in and complete the sign in process
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from <u>learn@houstonmethodist.org</u> with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

#### DISCLAIMER AND DISCLOSURES

Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.



Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

Name	Role	Relevant Financial Relationship(s)
Arvind Bhimaraj, MD, MPH, FACC, FHFSA	Speaker/Moderator	Consultant: CareDx
Maryjane Farr, MD, MSc, FACC, FAST	Speaker	Planning (Steering Committee)-TransMedics
Ashrith Guha, MD, MPH FACC	Speaker/Planner	Speaker: Actelion; Bayer; Abbott; Consultant/Advisory Board: Cytokinetics
Shelley Hall, MD, FACC, FHFSA, FAST	Speaker/Moderator	Consultant/Advisor: Natera; CareDx; Abbott; Abiomed; Medtronic
Annette M Jackson, PhD, F(ACHI)	Speaker/Moderator	Consultant: Hansan BioPharma; Speaker: Novartis; Researcher: CareDx; Speaker: One Lambda
Marlena Habal, MD, FRCPC	Speaker/Moderator	Investigator: Bristol Myer Squibb
Ju Kim, MD, FACC	Moderator	Consultant: CareDx

All the relevant financial relationships listed for these individuals have been mitigated.

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.



## **EXHIBITORS**

We gratefully acknowledge the following companies for participating as exhibitors at this activity:

# Astellas CareDx Takeda